UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~January 617, ~~2011~~2012

ZYTO CORP

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-54170 (Commission File Number)	20-5534033 (IRS Employer Identification Number)

	387 South 520 West, Suite 200 Lindon, UT 84042

801-224-7199 (Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 58.~~07 Submission~~01 Other ~~of Matters to a Vote of Security Holders~~Items.

~~Annual~~On ~~Shareholder~~January ~~Meeting~~23, –2012, ~~Voting~~ZYTO ~~Results~~Corp (the “Company”) announced that it had received notice and confirmation from the United States Patent and Trademark Office (“USPTO”) stating that the Company’s patent application for “Methods and Devices for Analyzing and Comparing Physiological Parameter Measurements” (the “Patent”) was issued on January 17, 2012, and given Patent No. 8,099,159.

OnThe ~~December~~Patent 6,covers ~~2011,~~the ~~ZYTO~~methods ~~Corp,~~and adevices ~~Delaware~~that ~~corporation~~are (capable of measuring physiological parameters of at least two contact points and determining whether the ~~“Company”~~measured parameters reflect favorable or ~~“ZYTO”),~~unfavorable ~~held~~physiological ~~its~~responses ~~2011~~are ~~Annual~~disclosed ~~Meeting~~herein. ofAs ~~Shareholders~~noted (in the ~~“Meeting”)~~application atfor the ~~offices~~Patent offiled with the ~~Company~~USPTO, inthe ~~Lindon,~~invention ~~Utah. The~~encompasses ~~following~~a ~~matters~~method ~~were~~that ~~voted~~can onnon-invasively monitor physiological parameters of at least two contact points before and after a stimulus is applied to a subject and compare the ~~Meeting:~~measured parameters to determine whether the physiological state of the subject is favorable or unfavorable.

~~(1) To~~The ~~elect~~Company ~~two~~uses ~~Class~~the ~~III~~patented ~~directors~~method of measuring the ~~Company~~skin’s togalvanic ~~hold~~response ~~office~~to ~~for~~stimuli ato ~~term~~provide ofinformation ~~three~~to ~~years~~healthcare ~~and~~professionals ~~until~~about ~~their~~an ~~successors~~individual’s ~~are~~health ~~elected~~ and ~~shall~~healthcare ~~qualify;~~options.

~~(2) To~~Dr. ~~ratify~~Vaughn ~~the~~R ~~Audit~~Cook ~~Committee’s~~is ~~selection~~listed ~~of Hansen Barnett & Maxwell, P.C.~~ as the ~~Independent~~inventor, ~~Registered~~and ~~Public~~Dr. ~~Accounting~~Cook ~~Firm~~has ~~and~~assigned ~~Auditor of~~ the ~~Company~~Patent ~~for~~to the ~~year ending December 31, 2011;~~Company.

The grant of the Patent follows the notification received from the US Food and Drug Administration (3the “FDA”) To ~~approve~~in ~~and~~August ~~adopt~~2011, that the Company’s ~~2011~~Premarket ~~Equity~~Notification ~~Incentive~~(the ~~Plan;~~“Notification”), submitted pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act (the “Act”) had been approved. The Company filed the Notification in May of 2011, and on August 30, 2011, the FDA issued its determination that the Hand Cradle was substantially equivalent to other Galvanic skin response measurement devices.

~~(4) To~~Item ~~amend~~7.01. Regulation ~~the~~FD ~~Company’s Certificate of Incorporation to increase the authorized capital stock of the Company to include 200,000,000 shares of common stock~~Disclosure.

~~Set~~On ~~forth~~January ~~below~~23, ~~are~~2012, the ~~voting~~Company ~~results~~issued ~~for~~a ~~each~~press ~~proposal~~release ~~submitted~~announcing tothe agrant ~~vote~~ of the ~~shareholders~~Patent atby the ~~Meeting~~USPTO. ~~For~~The ~~more~~press ~~information~~release onis ~~the~~attached ~~above-listed~~hereto ~~proposals, see the Company’s definitive proxy statement on Schedule 14A,~~ as ~~filed~~Exhibit ~~with~~99.1 ~~the~~to ~~Securities~~this ~~and Exchange Commission on October 26, 2011~~Report.

~~The~~In ~~voting~~accordance ~~totals~~with ~~were~~General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as ~~follows:~~amended, nor shall it be deemed incorporated by reference in any filing.

1Item 9. ~~Election~~01 Financial ofStatements ~~Class~~and ~~III Directors:~~Exhibits

Name of Director	Shares voted FOR	Shares voted AGAINST	Shares ABSTAINING	Shares WITHHELD
	(d)	Exhibits.
Sherman B. Hawkes	19,254,735	0	0	69,265
		99.1	Press Release dated January 23, 2012
Matthew DeVries	19,255,700	0	0	68,300

2. To ratify the Audit Committee’s selection of Hansen Barnett & Maxwell, P.C. as the Independent Registered Public Accounting Firm and Auditor of the Company for the year ending December 31, 2011:

Shares voted FOR	Shares voted AGAINST	Shares ABSTAINING
26,016,493	1,210,550	340,318

3. To approve and adopt the Company’s 2011 Equity Incentive Plan:

Shares voted FOR	Shares voted AGAINST	Shares ABSTAINING
17,846,225	645,975	831,800

4. To amend the Company’s Certificate of Incorporation to increase the authorized capital stock of the Company to include 200,000,000 shares of common stock:

Shares voted FOR	Shares voted AGAINST	Shares ABSTAINING
24,451,986	2,163,575	951,800

Item 5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Officers.

Election of New Directors

At the Company’s Annual Meeting discussed above, two new Class III directors, Sherman B. Hawkes and Matthew

DeVries, were elected to serve and to hold office for a term of three years and until their successors are elected and shall qualify. Biographical information for Messrs Hawkes and DeVries is as follows:

Sherman Hawkes, age 64, has served as the CEO and President of Hawkes & Company, LLC since May 2008. Prior to Hawkes & Company, LLC, Mr. Hawkes spent three years serving as Vice President of Business Development for Borrego Springs Bank and US Bank. He has over 25 years of management and consulting experience with numerous financial and real estate institutions across the United States. He has served on the US Bank of Utah Management Board; has served as CEO and Chairman of the Board of Clarus Corporation; and has served with the Special Panel of Trustees, Examiners and Receivers of the US Federal Bankruptcy Court, the Board of Directors of the CCIM of Utah, the Institute of Real Estate Management Executive Committee of Utah, and the Advisory Board of Directors of Century 21 National Corporation.

Mr. Hawkes has helped take over several troubled companies, and has reorganized them, paid off creditors in full, and continued the operation of the companies until they were sold to benefit the investors and stockholders.

While working with US Bank NA, Mr. Hawkes was charged with implementing training, marketing and management of the Small Business (SBA) Development Division covering all branch offices and business development officers in a 5-western-state area. He raised US Bank from 14th position to 2nd in Utah while working on political action committees contributing to pass key federal small business legislation for the SBA 504 and 7a lending programs, coordinating with US House of Representatives and Senate Small Business and Finance Committees.

Mr. Hawkes is a graduate of Dixie State College in St. George Utah. He holds a Degree in Marketing and Business Management from Brigham Young University in Provo, Utah, and a CPM from the Institute of Real Estate Management in Chicago Illinois.

Matthew DeVries, age 49, has served as the Chief Financial Officer of Vu1 Corporation (OTC:BB VUOC) since October, 2006. Vu1 Corporation is a New York based manufacturer and distributor of Electron Stimulated Luminescence™ light bulbs. In addition, Mr. DeVries has been an independent financial consultant since 2001, providing numerous public corporations and their board of directors financial and accounting guidance related to fundraising, acquisitions, divestitures, complex transactions and public company reporting in his consulting practice.

Departure of Directors

In connection with the election of Messrs. Hawkes and DeVries at the Meeting, the two previous Class III Directors, Beverly Clark and Glen Miner, were not nominated to serve as Directors of the Company, and as such have ended their service.

The Board of Directors and Management of the Company express their sincere gratitude to Ms. Clark and Mr. Miner for their service and devotion to the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

	ZYTO Corp
Date: December 12, 2011	By: /s/ Vaughn R Cook
Date: January 23, 2012	By: /s/ Vaughn R Cook
	Name: Vaughn R Cook
	Title: Chief Executive Officer

Filing Compare · ZYTO CORP